@article{ee9cb1974b58495381c7b0e4f261b50b,
title = "Etrolizumab for ulcerative colitis: beyond what meets the eye",
author = "Manasi Agrawal and Bram Verstockt",
note = "Funding Information: MA declares no competing interests. BV reports financial support for research from Pfizer; consultancy fees from Applied Strategic, Atheneum, Bristol Myers Squibb, Guidepont, Ipsos, Janssen, Progenity, Sandoz, and Takeda; and lecture fees from AbbVie, Biogen, Chiesi, Falk, Ferring, Galapagos, Janssen, MSD, Pfizer, R-Biopharm, Takeda, and Truvion, outside of the submitted work. MA is supported by the US National Institute of Diabetes and Digestive and Kidney Diseases (K23DK129762-01). BV is supported by the Clinical Research Fund (KOOR) at the University Hospitals Leuven, Leuven, Belgium. We thank academic medical illustrator Jill Gregory (Icahn School of Medicine at Mount Sinai, New York, NY, USA) for assistance with figure design.",
year = "2022",
month = jan,
doi = "10.1016/S2468-1253(21)00369-1",
language = "English",
volume = "7",
pages = "2--4",
journal = "The Lancet Gastroenterology and Hepatology",
issn = "2468-1253",
publisher = "Elsevier Ltd.",
number = "1",
}